Publication

Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [C-11]verapamil as a probe for P-glycoprotein function

de Klerk, O. L., Willemsen, A. T. M., Bosker, F. J., Bartels, A. L., Hendrikse, N. H., den Boer, J. A. & Dierckx, R. A., 30-Aug-2010, In : Psychiatry research-Neuroimaging. 183, 2, p. 151-156 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

P-glycoprotein (P-gp), a major efflux pump in the blood-brain barrier (BBB) has a profound effect on entry of drugs, peptides and other substances into the central nervous system (CNS). The brain's permeability can be negatively influenced by modulation of the transport function of P-gp. Inflammatory mediators play a role in schizophrenia, and may be able to influence the integrity of the BBB, via P-gp modulation. We hypothesized that P-gp function in the BBB is changed in patients with schizophrenia. Positron-emission tomography was used to measure brain uptake of [C-11]verapamil, which is normally extruded from the brain by P-gp. We found that patients with chronic schizophrenia under treatment with antipsychotic drugs compared with healthy controls showed a significant decrease in [C-11]verapamil uptake in the temporal cortex, the basal ganglia, and the amygdala, and amygdalae, and a trend towards a significant decrease was seen throughout the brain. The decrease of [C-11]verapamil uptake correlates with an increased activity of the P-gp pump. Increased P-gp activity may be a factor in drug resistance in schizophrenia, induced by the use of antipsychotic agents. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)151-156
Number of pages6
JournalPsychiatry research-Neuroimaging
Volume183
Issue number2
Publication statusPublished - 30-Aug-2010

    Keywords

  • P-glycoprotein, Positron emission tomography, [C-11]verapamil, Schizophrenia, Blood-brain barrier, MDR1 GENE POLYMORPHISMS, NECROSIS-FACTOR-ALPHA, RISPERIDONE TREATMENT, THERAPEUTIC RESPONSE, ANTIPSYCHOTIC-DRUGS, PARKINSONS-DISEASE, TRANSPORT ACTIVITY, ABCB1 GENE, IN-VITRO, EXPRESSION

ID: 5142626